Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benaglutide for nonalcoholic steatohepatitis in adults with type 2 diabetes mellitus
ChiCTR1900023611Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of beinaglutide in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Change in intrahepatic triglyceride content at 24 weeks and Change in hepatic stiffness at 24 weeks. Started Jan 2018; status: recruiting.
02
Drugs
beinaglutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ChiCTR1900023611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023611.